GlassScriptPhysician profile
Kunjal Patel
NPI 1457978660
$2,546.34
in general payments reported to CMS, 2019-2025
19 companies · $851 in 2025
The $851 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $78.93 · 2023: $438 · 2024: $1,178 · 2025: $851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,467.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $576.13 | 2024-2025 | Korlym |
| Lilly USA, LLC | $345.62 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Alexion Pharmaceuticals, INC. | $177.14 | 2025 | |
| Janssen Pharmaceuticals, INC | $160.28 | 2022-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $123.72 | 2023 | |
| Neurocrine Biosciences, INC. | $116.74 | 2025 | |
| Medtronic, INC. | $115.12 | 2025 | Minimed 780g |
| Bayer Healthcare Pharmaceuticals INC. | $114.66 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $104.64 | 2024 | |
| Xeris Pharmaceuticals, INC. | $100.78 | 2025 | Recorlev |
| Horizon Therapeutics Plc | $98.28 | 2023 | Tepezza |
| Amgen INC. | $97.02 | 2025 | Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.64 | 2024 | Jardiance |
| Madrigal Pharmaceuticals | $78.40 | 2024 | Rezdiffra |
| Tandem Diabetes Care, INC. | $75.12 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $73.28 | 2024 | Omnipod |
| Radius Health, INC. | $49.54 | 2024 | Tymlos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $46.75 | 2022-2023 | Lifevest |
| Alnylam Pharmaceuticals INC. | $12.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kunjal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.